𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study

✍ Scribed by Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
321 KB
Volume
24
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD‐related ED. Twelve patients with PD and disabling ED completed an 8‐week pilot open‐label, flexible dose (25–100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression‐Change Scale (75% positive response rate; 95% CI: 43–95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials. © 2008 Movement Disorder Society

📜 SIMILAR VOLUMES

Caffeine in Parkinson's disease: A pilot
Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
✍ Robert D. Altman; Anthony E. Lang; Ronald B. Postuma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB 👁 1 views

## Abstract ## Introduction: Epidemiologic studies consistently find an inverse association between caffeine use and PD. Numerous explanations exist, but are difficult to evaluate as caffeine's symptomatic effect and tolerability in PD are unknown. ## Patients and Methods: We designed an open‐la

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; John L. Maldonado; William O. Tatum; Ro 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and wer

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo

Symptomatic relief from treatment-induce
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: An open-label pilot study with remoxipride
✍ Dr. Tilak Mendis; Erich Mohr; Amanda George; Ilene N. Rusk; Peggy Gray; J. David 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 1 views

## Abstract Current treatment strategies for levodopa‐induced psychosis in Parkinson's disease have had limited success. Remoxipride, a selective D~2~ receptor antagonist, was administered in an open label pilot study to seven parkinsonian patients exhibiting thought disorder. Symptoms improved sig

Extracorporeal photopheresis for the tre
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study
✍ Maria T. Abreu; Christian von Tirpitz; Robert Hardi; Martin Kaatz; Gert Van Assc 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 2 views

## Background: Extracorporeal photopheresis (ecp) is effective in immune-mediated disorders. a prospective, uncontrolled pilot study was conducted to evaluate the safety and efficacy of ecp in patients with active crohn's disease (cd) who were refractory to or intolerant of immunosuppressants and/o

Duloxetine in the treatment of irritable
Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study
✍ Brian P. Brennan; Kate V. Fogarty; Jacqueline L. Roberts; Karina A. Reynolds; Ha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). ## Methods We conducted an open‐label 12‐week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder. The primary outcome measure was average abdominal